Cagrilintide Demonstrates Significant Weight Loss and Metabolic Improvements in Preclinical Obesity Model

The global prevalence of obesity continues to rise, leading to severe health complications such as type 2 diabetes, non-alcoholic fatty liver disease (NAFLD), and cardiovascular disease. Despite existing treatments, there remains a critical need for novel, highly effective, and well-tolerated pharmacotherapies. This preclinical study aimed to investigate the therapeutic potential of Cagrilintide, a synthetic amylin analog, to address the complex pathophysiology of obesity and its associated metabolic dysfunctions.

Treatment with Cagrilintide resulted in profound and statistically significant reductions in body weight and substantial improvements across multiple metabolic markers. > The high-dose Cagrilintide group exhibited a remarkable 23.5% reduction in body weight compared to the vehicle control group by week 12 (p<0.001), while the low-dose group achieved a significant 15.8% reduction (p<0.01). This weight loss was primarily driven by a substantial decrease in cumulative food intake, which was reduced by 38% in the high-dose group and 25% in the low-dose group compared to controls (p<0.001 for both). Beyond weight, glucose homeostasis was markedly improved; the high-dose group showed a 35% lower area under the curve (AUC) during the oral glucose tolerance test (p<0.001), indicating enhanced insulin sensitivity. Furthermore, plasma triglyceride levels were 28% lower (p<0.05) and total cholesterol was 18% lower (p<0.05) in the high-dose Cagrilintide group, suggesting beneficial effects on lipid metabolism.